Monday 19 April: 08.00 - 09.00 am AEST
Preliminary analgesic evidence of cannabinoids delivered via NanoCelle® (submicron particle technology) and its further research addressing gaps in cannabis dosing efficacy
Results of a completed clinical study at RNSH investigating the pharmacokinetics (PK), safety, and tolerability of THC and CBD cannabinoids in a unique NanoCelle® formulation for the management of unrelieved pain in patients diagnosed with advanced cancers. Medlab’s water-soluble nanoparticle delivered cannabis-based medicine showed superior bioavailability and tolerability compared to ethanol-based delivery of cannabis-based medicines across the oro-buccal mucous membrane. The results of the study have demonstrated acceptable bioavailability, safety, tolerability, and evidence of analgesic efficacy in advanced cancers with bone metastasis.
Presenting an update on current research is important for those physicians who are currently prescribing medicinal cannabis for the patients where traditional therapies have failed. The level of current evidence on medicinal cannabis efficacy is low-moderated, and further research is needed for the safety of patients.
Dr Jeremy Henson is Medical Affairs Director at Medlab Clinical, Botany; Chief Career Medical Officer at Lakeview Private Hospital, Bella Vista; Senior Research Fellow at UNSW Sydney. Dr Henson has 18 years’ experience in cancer research, including the discovery of a novel type of cancer biomarker, development of a patented an assay to detect it and is exploiting these to create new precision cancer medicines. Dr Henson is a Clinical Tutor at the Faculty of Medicine, UNSW Sydney and is an active member of Cancer Australia Grant Review Committee and the Prince of Wales Clinical School PhD Student Review Committee.
Tuesday 20 April, Morning Sessions